78 related articles for article (PubMed ID: 8595507)
1. Individualization of therapy using viral markers.
Merigan T
J Acquir Immune Defic Syndr Hum Retrovirol; 1995; 10 Suppl 1():S41-6. PubMed ID: 8595507
[TBL] [Abstract][Full Text] [Related]
2. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
Van Vaerenbergh K
Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
[TBL] [Abstract][Full Text] [Related]
3. Viral phenotype and genotype as markers in clinical trials.
Katzenstein DA
J Acquir Immune Defic Syndr Hum Retrovirol; 1995; 10 Suppl 2():S25-34. PubMed ID: 7552510
[TBL] [Abstract][Full Text] [Related]
4. HIV viral load quantification, HIV resistance, and antiretroviral therapy.
Katzenstein DA; Holodniy M
AIDS Clin Rev; 1995-1996; ():277-303. PubMed ID: 7488557
[TBL] [Abstract][Full Text] [Related]
5. Antiretroviral treatment. HIV infection in adults: better-defined first-line treatment.
Prescrire Int; 2004 Aug; 13(72):144-50. PubMed ID: 15532140
[TBL] [Abstract][Full Text] [Related]
6. Triple combinations: present and future.
Lange JM
J Acquir Immune Defic Syndr Hum Retrovirol; 1995; 10 Suppl 1():S77-82. PubMed ID: 8595515
[TBL] [Abstract][Full Text] [Related]
7. Molecular biological assessment methods and understanding the course of the HIV infection.
Katzenstein TL
APMIS Suppl; 2003; (114):1-37. PubMed ID: 14626050
[TBL] [Abstract][Full Text] [Related]
8. Replication capacity, biological phenotype, and drug resistance of HIV strains isolated from patients failing antiretroviral therapy.
Nicastri E; Sarmati L; d'Ettorre G; Palmisano L; Parisi SG; Uccella I; Rianda A; Concia E; Vullo V; Vella S; Andreoni M
J Med Virol; 2003 Jan; 69(1):1-6. PubMed ID: 12436471
[TBL] [Abstract][Full Text] [Related]
9. Zidovudine and lamivudine: results of phase III studies.
Staszewski S
J Acquir Immune Defic Syndr Hum Retrovirol; 1995; 10 Suppl 1():S57. PubMed ID: 8595510
[TBL] [Abstract][Full Text] [Related]
10. Mutations linked to drug resistance, human immunodeficiency virus type 1 biologic phenotype and their association with disease progression in children receiving nucleoside reverse transcriptase inhibitors.
Englund JA; Raskino C; Vavro C; Palumbo P; Ross LL; McKinney R; Nikolic-Djokic D; Colgrove RC; Baker CJ;
Pediatr Infect Dis J; 2004 Jan; 23(1):15-22. PubMed ID: 14743040
[TBL] [Abstract][Full Text] [Related]
11. [Recommendations from the GESIDA/Spanish AIDS Plan regarding antiretroviral treatment in adults with human immunodeficiency virus infection (update February 2009)].
Panel de expertos de Gesida y Plan Nacional sobre el Sida
Enferm Infecc Microbiol Clin; 2009 Apr; 27(4):222-35. PubMed ID: 19246124
[TBL] [Abstract][Full Text] [Related]
12. Studies of zidovudine in combination with didanosine and zalcitabine.
Jablonowski H
J Acquir Immune Defic Syndr Hum Retrovirol; 1995; 10 Suppl 1():S52-6. PubMed ID: 8595509
[TBL] [Abstract][Full Text] [Related]
13. Genotypic resistance and HIV-1 subtype in Brazilian children on dual and triple combination therapy.
Machado ES; Lambert JS; Watson DC; Afonso AO; da Cunha SM; Nogueira SA; Caride E; Oliveira RH; Sill AM; DeVico A; Tanuri A
J Clin Virol; 2004 May; 30(1):24-31. PubMed ID: 15072750
[TBL] [Abstract][Full Text] [Related]
14. Current HIV clinical trial design issues.
Lange JM
J Acquir Immune Defic Syndr Hum Retrovirol; 1995; 10 Suppl 1():S47-51. PubMed ID: 8595508
[TBL] [Abstract][Full Text] [Related]
15. Resistance testing debate: does it make the grade?
Simmons P
Res Initiat Treat Action; 1999 Oct; 5(4):9-12. PubMed ID: 11366943
[TBL] [Abstract][Full Text] [Related]
16. Impact of drug resistance genotypes on CD4+ counts and plasma viremia in heavily antiretroviral-experienced HIV-infected patients.
Rodes B; García F; Gutierrez C; Martinez-Picado J; Aguilera A; Saumoy M; Vallejo A; Domingo P; Dalmau D; Ribas MA; Blanco JL; Pedreira J; Perez-Elias MJ; Leal M; de Mendoza C; Soriano V;
J Med Virol; 2005 Sep; 77(1):23-8. PubMed ID: 16032728
[TBL] [Abstract][Full Text] [Related]
17. Antiretroviral therapy in 1999 for antiretroviral-naive individuals with HIV infection.
Fischl MA
AIDS; 1999 Sep; 13 Suppl 1():S49-59. PubMed ID: 10546785
[TBL] [Abstract][Full Text] [Related]
18. Resistance testing.
Munk B
Posit Aware; 1997; 8(4):35-7. PubMed ID: 11364486
[TBL] [Abstract][Full Text] [Related]
19. Genotypic resistance tests for the management of the HIV-infected pregnant woman.
Bassetti D; Cargnel A
Scand J Infect Dis Suppl; 2003; 106():70-4. PubMed ID: 15000589
[TBL] [Abstract][Full Text] [Related]
20. A comparison of three computational modelling methods for the prediction of virological response to combination HIV therapy.
Wang D; Larder B; Revell A; Montaner J; Harrigan R; De Wolf F; Lange J; Wegner S; Ruiz L; Pérez-Elías MJ; Emery S; Gatell J; D'Arminio Monforte A; Torti C; Zazzi M; Lane C
Artif Intell Med; 2009 Sep; 47(1):63-74. PubMed ID: 19524413
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]